Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Bacterial infections cause millions of deaths globally, particularly in children and the elderly, and four of the 10 leading causes of death are infectious diseases in low- and middle-income countries. The continuous use of antibiotics has resulted in multi-resistant bacterial strains all over the world, such as Community-associated Methicillin-resistant Staphylococcus aureus (MRSA), extended-spectrum β-lactamases (ESBLs), and, as expected, hospitals have become breeding grounds for human-associated microorganisms, especially in critical care units.

Research & information: general --- Biology, life sciences --- actinomycetes --- antibiotic biosynthesis --- silent biosynthetic pathways --- γ-butyrolactones --- HiTES --- translation inhibitors --- marine actinobacteria --- Streptomyces sp. --- enzyme inhibition --- antimicrobial --- antioxidant --- cytotoxicity --- GC-MS --- pyrrolopyrazines --- myxobacteria --- antivirals --- secondary metabolites --- HIV --- Ebola --- hepatitis viruses --- diversity --- uncultured --- new antibiotics --- Streptomyces --- polyketides --- secondary metabolite --- polyketide synthases (PKSs) --- actinomycetes --- antibiotic biosynthesis --- silent biosynthetic pathways --- γ-butyrolactones --- HiTES --- translation inhibitors --- marine actinobacteria --- Streptomyces sp. --- enzyme inhibition --- antimicrobial --- antioxidant --- cytotoxicity --- GC-MS --- pyrrolopyrazines --- myxobacteria --- antivirals --- secondary metabolites --- HIV --- Ebola --- hepatitis viruses --- diversity --- uncultured --- new antibiotics --- Streptomyces --- polyketides --- secondary metabolite --- polyketide synthases (PKSs)

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Microbial natural products have been an important traditional source of valuable antibiotics and other drugs but interest in them waned in the 1990s when big pharma decided that their discovery was no longer cost-effective and concentrated instead on synthetic chemistry as a source of novel compounds, often with disappointing results. Moreover understanding the biosynthesis of complex natural products was frustratingly difficult. With the development of molecular genetic methods to isolate and manipulate the complex microbial enzymes that make natural products, unexpected chemistry has been

Biosynthesis. --- Carbohydrates -- Synthesis. --- Microbial biotechnology. --- Peptides -- Synthesis. --- Polyketides -- Synthesis. --- Metabolism --- Carbon-Carbon Ligases --- Multienzyme Complexes --- Complex Mixtures --- Biochemical Processes --- Chemicals and Drugs --- Enzymes and Coenzymes --- Chemical Processes --- Biochemical Phenomena --- Ligases --- Metabolic Phenomena --- Chemical Phenomena --- Phenomena and Processes --- Peptide Biosynthesis --- Polyketide Synthases --- Enzymes --- Biological Products --- Carbohydrates --- Human Anatomy & Physiology --- Health & Biological Sciences --- Animal Biochemistry --- Peptides --- Polyketides --- Synthesis. --- Peptide synthesis --- Acetogenins --- Biological synthesis --- Synthesis, Biological --- Ketenes --- Polymers --- Biochemical engineering --- Biochemistry --- Organic compounds --- Synthetic biology --- Biochemical templates --- Synthesis

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Beyond being the most important natural compound source, actinomycetes are the origin of up to two-thirds of all clinically used antibiotics. Currently, new antimicrobials are urgently needed, as infections caused by antibiotic-resistant pathogens are on the rise. In the identification of new antibiotics, many scientists are currently investigating biosynthetic aspects of antibiotic production in actinomycetes. Since the emergence of next-generation sequencing technologies, the field of antibiotics research has experienced a remarkable revival. These bacteria have the potential to produce more antibiotics than previously thought possible. Some antibiotics are produced in standard media, while others require the presence of a specific signaling molecule in the medium. Others, however, are only produced when the native regulation of the biosynthesis gene cluster is overruled. This book covers topics in the field of antibiotic-producing actinomycetes. The following tops are addressed: - Approaches to access novel antibiotic producers for novel natural compounds - Omics and genome mining approaches for the discovery of novel natural compounds - Analyses and genetic engineering of antibiotic biosynthesis - Regulation of the secondary metabolism in actinomycetes

Research & information: general --- Biology, life sciences --- Streptomyces --- biogeography --- comparative genomics --- diversification --- secondary metabolite biosynthetic gene clusters --- SMGC --- natural products --- streptomyces --- rishirilide --- biosynthesis --- polyketides --- polynucleotide phosphorylase --- ribonuclease --- regulation --- promoter --- RNA decay --- polyadenylation --- (p)ppGpp --- antibiotic --- antibiotics --- geomicrobiology --- Illumina sequencing --- microbiome diversity --- Actinobacteria --- Cave microbiology --- secondary metabolite --- rare Actinobacteria --- Amycolatopsis --- unculturability --- siderophore --- glycopeptide antibiotics --- dbv cluster --- regulatory genes --- StrR --- LAL --- LuxR solo --- dalbavancin --- A40926 --- Streptomyces lividans --- secretion pathways --- secretory proteins --- signal peptides --- actinomycetes --- teicoplanin --- van resistance genes --- Streptomyces tsukubaensis --- tacrolimus --- FK506 --- omics --- screening --- secondary metabolism --- differentiation --- elicitors --- morphology --- liquid cultures --- metagenomics --- rare actinomycetes --- dereplication --- metabolomics --- genome mining --- secondary metabolites --- novel compounds --- physicochemical screening --- physical and chemical properties --- structural diversity --- biological activity --- Actinoallomurus --- antibiotics polyethers --- lysolipin --- minimal PKS II --- cyclases --- benz[a]naphthacene quinone --- tridecaketide --- aromatic polyketide --- pentacyclic angular polyphenol --- extended polyketide chain --- actinobacteria --- β-lactamase --- resistance --- β-lactamase inhibitor --- polyketide synthases --- acyltransferases --- engineering --- new bioactive compounds --- symbiosis --- drug discovery --- chemical ecology --- culture-based approaches --- strain --- specialized metabolites --- biosynthetic gene cluster --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

There has been much speculation about a possible antibiotic Armageddon; this would be the result of having untreatable post-operative infections, and similarly untreatable complications after chemotherapy. The now famous “O’Neill Report” (https://amr-review.org/) suggests that more people could die from resistant bacterial infections by 2050 than from cancer. We are still learning about all the subtle drivers of antibiotic resistance, and realizing that we need a single “whole of health” co-ordinated policy. We ingest what we sometimes feed to animals. There do not seem to be any new classes of antibiotics on our horizon. Perhaps something that has been around “forever” will come to our rescue—bacteriophages! Nevertheless, we have to do things differently, use antibiotics appropriately, for the correct indication, for the correct duration and with the correct dose, and with that, practice good antibiotic stewardship. Whilst by no means comprehensive, this book does cover some of the many topics of antibiotic stewardship. It also addresses some of the older antibiotics, some new combinations, and even some new agents. Last, and by no means least, there are two excellent articles on bacteriophages.

Antimicrobial resistance --- antibiotics --- antimicrobial stewardship --- inappropriate prescribing --- days of therapy --- Start Smart then Focus --- piperine --- piperlongumine --- antibacterial --- antifungal --- synergy --- non-target feed --- florfenicol --- thiamfenicol --- chloramfenicol --- HPLC–MS/MS --- validation --- swine --- out-of-hours care --- primary care --- quality of care --- quality indicators --- practitioners cooperative --- antibiotic stewardship --- fluoroquinolones --- guidelines --- urinary tract infections --- quality improvement --- general practitioners --- guideline --- health inequalities --- health equity assessment tool --- public health --- Enterobacteriaceae --- carbapenem-resistant --- CRE --- antibiotic resistance --- antimicrobials --- bacteriophages --- biofilms --- novel antimicrobials --- Antibiotics --- resistance --- broad-spectrum agents --- hospital epidemiology --- antibiotic utilization --- infection control --- infection prevention --- Pseudomonas aeruginosa --- Acinetobacter baumannii --- extended-spectrum beta-lactamases --- carbapenem-resistant Enterobacteriaceae --- methicillin-resistant Staphylococcus aureus --- clinical trials --- infectious disease --- phage therapy --- silver complexes --- camphorimine --- anti-Candida activity --- antifungals --- antibacterials --- efflux inhibitors --- efflux pumps --- erm(41) --- mutations --- mycobacteria --- verapamil --- actinomycetes --- bioactivity --- polyketides --- polyketide synthases --- biosynthesis --- antimicrobial resistance --- economic evaluation --- cost-utility analysis --- cost-effectiveness analysis --- policy analysis --- One Health --- Singapore --- antibiotic prescribing --- implementation --- behavior change --- stakeholder consultation --- n/a --- HPLC-MS/MS

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

There has been much speculation about a possible antibiotic Armageddon; this would be the result of having untreatable post-operative infections, and similarly untreatable complications after chemotherapy. The now famous “O’Neill Report” (https://amr-review.org/) suggests that more people could die from resistant bacterial infections by 2050 than from cancer. We are still learning about all the subtle drivers of antibiotic resistance, and realizing that we need a single “whole of health” co-ordinated policy. We ingest what we sometimes feed to animals. There do not seem to be any new classes of antibiotics on our horizon. Perhaps something that has been around “forever” will come to our rescue—bacteriophages! Nevertheless, we have to do things differently, use antibiotics appropriately, for the correct indication, for the correct duration and with the correct dose, and with that, practice good antibiotic stewardship. Whilst by no means comprehensive, this book does cover some of the many topics of antibiotic stewardship. It also addresses some of the older antibiotics, some new combinations, and even some new agents. Last, and by no means least, there are two excellent articles on bacteriophages.

Medicine --- Antimicrobial resistance --- antibiotics --- antimicrobial stewardship --- inappropriate prescribing --- days of therapy --- Start Smart then Focus --- piperine --- piperlongumine --- antibacterial --- antifungal --- synergy --- non-target feed --- florfenicol --- thiamfenicol --- chloramfenicol --- HPLC-MS/MS --- validation --- swine --- out-of-hours care --- primary care --- quality of care --- quality indicators --- practitioners cooperative --- antibiotic stewardship --- fluoroquinolones --- guidelines --- urinary tract infections --- quality improvement --- general practitioners --- guideline --- health inequalities --- health equity assessment tool --- public health --- Enterobacteriaceae --- carbapenem-resistant --- CRE --- antibiotic resistance --- antimicrobials --- bacteriophages --- biofilms --- novel antimicrobials --- Antibiotics --- resistance --- broad-spectrum agents --- hospital epidemiology --- antibiotic utilization --- infection control --- infection prevention --- Pseudomonas aeruginosa --- Acinetobacter baumannii --- extended-spectrum beta-lactamases --- carbapenem-resistant Enterobacteriaceae --- methicillin-resistant Staphylococcus aureus --- clinical trials --- infectious disease --- phage therapy --- silver complexes --- camphorimine --- anti-Candida activity --- antifungals --- antibacterials --- efflux inhibitors --- efflux pumps --- erm(41) --- mutations --- mycobacteria --- verapamil --- actinomycetes --- bioactivity --- polyketides --- polyketide synthases --- biosynthesis --- antimicrobial resistance --- economic evaluation --- cost-utility analysis --- cost-effectiveness analysis --- policy analysis --- One Health --- Singapore --- antibiotic prescribing --- implementation --- behavior change --- stakeholder consultation --- Antimicrobial resistance --- antibiotics --- antimicrobial stewardship --- inappropriate prescribing --- days of therapy --- Start Smart then Focus --- piperine --- piperlongumine --- antibacterial --- antifungal --- synergy --- non-target feed --- florfenicol --- thiamfenicol --- chloramfenicol --- HPLC-MS/MS --- validation --- swine --- out-of-hours care --- primary care --- quality of care --- quality indicators --- practitioners cooperative --- antibiotic stewardship --- fluoroquinolones --- guidelines --- urinary tract infections --- quality improvement --- general practitioners --- guideline --- health inequalities --- health equity assessment tool --- public health --- Enterobacteriaceae --- carbapenem-resistant --- CRE --- antibiotic resistance --- antimicrobials --- bacteriophages --- biofilms --- novel antimicrobials --- Antibiotics --- resistance --- broad-spectrum agents --- hospital epidemiology --- antibiotic utilization --- infection control --- infection prevention --- Pseudomonas aeruginosa --- Acinetobacter baumannii --- extended-spectrum beta-lactamases --- carbapenem-resistant Enterobacteriaceae --- methicillin-resistant Staphylococcus aureus --- clinical trials --- infectious disease --- phage therapy --- silver complexes --- camphorimine --- anti-Candida activity --- antifungals --- antibacterials --- efflux inhibitors --- efflux pumps --- erm(41) --- mutations --- mycobacteria --- verapamil --- actinomycetes --- bioactivity --- polyketides --- polyketide synthases --- biosynthesis --- antimicrobial resistance --- economic evaluation --- cost-utility analysis --- cost-effectiveness analysis --- policy analysis --- One Health --- Singapore --- antibiotic prescribing --- implementation --- behavior change --- stakeholder consultation